NASDAQ · Biotechnology · USD

Hemab Therapeutics Holdings, Inc. (COAG) Stock Analysis

Hemab Therapeutics Holdings, Inc. (COAG) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

COAG

$44.41

+$0.04 (+0.09%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare COAG with… →

COAG Key Statistics

As of Sep 4, 2026

Trading

Open: $43.40
Previous Close: $44.37
Day's Range: 43.29–45.49
52-Week Range: 23.00–55.42
Volume: 302.00K

Valuation

Market Cap: $2.07B
P/E Ratio: unprofitable
EPS (ttm): −1.79

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$63.91M
Profit margin: 0.00%
Shares Outstanding: 46.71M

Dividend and dates

Earnings Date: November 16, 2026estimated
Avg Volume: 363.40K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

COAG Revenue and Earnings by Fiscal Year

FY ends December

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$63.91M	—
2024	$0.00	−$48.71M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$70.12M	−$63.91M	—
2024	$0.00	—	−$50.38M	−$48.71M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

COAG Valuation vs Biotechnology Median

Median of 656 stocks

Metric	COAG	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Hemab Therapeutics Holdings, Inc. (COAG) carries a market capitalisation of $2.07B. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 59 employees.

COAG last closed at $44.41 on September 4, 2026. That is +$0.04 (+0.09%) against the previous close. Over the past 52 weeks the price has ranged from $23.00 to $55.42. The latest close sits 93.09% above that 52-week low.

Financial Health

In fiscal 2025, Hemab Therapeutics Holdings, Inc. reported revenue of $0.00. The same year closed with a net loss of $63.91M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −1.79.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Growth & Income

No dividend is on file for COAG.

2026 is still running; the price is +30.62% year to date.

Peer Comparison

Hemab Therapeutics Holdings, Inc. (COAG) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Hemab Therapeutics Holdings, Inc.	COAG	$2.07B	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Hemab Therapeutics Holdings, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Hemab Therapeutics Holdings, Inc.

Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.

Visit website →